Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Peters, S; Paz-Ares, LG; Reck, M; Carbone, DP; Brahmer, JR; Borghaei, H; Lu, S; O’Byrne, KJ; John, T; Ciuleanu, TE; Schenker, M; Caro, RB; Nishio, M; Cobo, M; Lee, JS; Zurawski, B; Pluzanski, A; Aoyama, T; Tschaika, M; Devas, V; Grootendorst, DJ; Ramalingam, SS...

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial – JOURNAL OF CLINICAL ONCOLOGY

Tan, DSW; Felip, E; de Castro, G; Solomon, BJ; Greystoke, A; Cho, BC; Cobo, M; Kim, TM; Ganguly, S; Carcereny, E; Paz-Ares, L; Bennouna, J; Garassino, MC; Schenker, M; Kim, SW; Brase, JC; Bury-Maynard, D; Passos, VQ; Deudon, S; Dharan, B; Song, YB; Caparica, R;...